Background Only 15–20% of patients with chronic hepatitis C achieve a sustained virological
response with interferon therapy. The aim of this study was to compare the efficacy and …

One year of treatment with entecavir (0.5 mg daily) in nucleoside‐naive patients with hepatitis
B e antigen (HBeAg)‐positive or HBeAg‐negative chronic hepatitis B (CHB) resulted in …

Acute renal failure (ARF) is a common complication in patients with decompensated cirrhosis.
The traditional diagnostic criteria of renal failure in these patients were proposed in 1996 1 …

Background Chronic hepatitis C virus (HCV) infection in patients with cirrhosis is difficult to
treat. In patients with chronic hepatitis C but without cirrhosis, once-weekly administration of …

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In
study entecavir (ETV)‐022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for …

BACKGROUND & AIMS: Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and
potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir …

In cirrhosis, cardiac contractile function has been extensively documented to be abnormal. At
baseline, cardiac output is increased, and this is one of the characteristics of hyperdynamic …

A two-step paradigm for leukocyte recruitment has been established in a number of tissues
including the mesentery, skin, and muscle, and necessitates an initial rolling step via the …

Malnutrition is prevalent among cirrhotic patients and is an important prognostic factor.
Etiologic factors include hypermetabolism, malabsorption, altered nutrient metabolism, and …

Background The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen,
glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological …